METiS TechBio Debuts Strongly on Hong Kong Stock Market, Drawing SpaceX Comparison
AI-Driven Drug Design Start-Up Raises HK$2.11 Billion in IPO
نظرة سريعة
- METiS TechBio, an AI-driven drug design start-up, made a strong debut on the Hong Kong stock market, raising HK$2.11 billion.
- CEO Lai Tsai-Ta compared the company to SpaceX, highlighting its use of AI algorithms for rapid drug development through nano-delivery platforms.
ملخص مُنشأ بالذكاء الاصطناعي
METiS TechBio, an AI-driven drug design start-up, made a strong debut on the Hong Kong stock market, raising HK$2.11 billion. CEO Lai Tsai-Ta compared the company to SpaceX, highlighting its use of AI algorithms for rapid drug development through nano-delivery platforms.




